Cargando…

Long‐term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out‐patients with opioid use disorder

AIMS: To assess the long‐term safety of subcutaneous buprenorphine (CAM2038) weekly and monthly depots. DESIGN: Phase 3, open‐label, observational, multi‐centre 48‐week trial (ClinicalTrials.gov NCT02672111). SETTING: Twenty‐six out‐patient sites (United States, United Kingdom, Hungary, Denmark, Swe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Frost, Michael, Bailey, Genie L., Lintzeris, Nicholas, Strang, John, Dunlop, Adrian, Nunes, Edward V., Jansen, Jakob Billeskov, Frey, Lars Chemnitz, Weber, Bernd, Haber, Paul, Oosman, Sonia, Kim, Sonnie, Tiberg, Fredrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771955/ https://www.ncbi.nlm.nih.gov/pubmed/31013390 http://dx.doi.org/10.1111/add.14636

Ejemplares similares

Treatment of opioid dependence with depot buprenorphine (CAM2038) in custodial settings
por: Dunlop, Adrian J., et al.
Publicado: (2021)

Population Pharmacokinetic Analysis Supports Initiation Treatment and Bridging from Sublingual Buprenorphine to Subcutaneous Administration of a Buprenorphine Depot (CAM2038) in the Treatment of Opioid Use Disorder
por: Björnsson, Marcus, et al.
Publicado: (2023)

Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial
por: Lintzeris, Nicholas, et al.
Publicado: (2021)

Depot buprenorphine as an opioid agonist therapy in New South Wales correctional centres: a costing model
por: Ling, R., et al.
Publicado: (2022)

Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
por: Arunogiri, Shalini, et al.
Publicado: (2021)

Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences
por: Neale, Joanne, et al.
Publicado: (2019)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

Evaluation of the Effects of a Monthly Buprenorphine Depot Subcutaneous Injection on QT Interval During Treatment for Opioid Use Disorder
por: Schmith, Virginia D., et al.
Publicado: (2019)

Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study
por: Larance, Briony, et al.
Publicado: (2020)

Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis
por: Andorn, Anne C., et al.
Publicado: (2020)

Depot Buprenorphine Injection In The Management Of Opioid Use Disorder: From Development To Implementation
por: Ling, Walter, et al.
Publicado: (2019)

Depot Buprenorphine Injection in the Management of Opioid Use Disorder: From Development to Implementation [Corrigendum]
Publicado: (2020)

Patient perspectives on depot buprenorphine treatment for opioid addiction – a qualitative interview study
por: Johnson, Björn, et al.
Publicado: (2022)

Addiction Recovery Among Opioid-Dependent Patients Treated With Injectable Subcutaneous Depot Buprenorphine: Study Protocol of a Non-randomized Prospective Observational Study (ARIDE)
por: Schulte, Bernd, et al.
Publicado: (2020)

Food allergy and anaphylaxis – 2038. Insect and sting allergy
por: Husain, Syed Arham
Publicado: (2013)

Design and in vivo evaluation of a microparticulate depot formulation of buprenorphine for veterinary use
por: Schreiner, Viktoria, et al.
Publicado: (2020)

Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review
por: Lintzeris, Nicholas, et al.
Publicado: (2022)

Future Incidence of Malignant Mesothelioma in South Korea: Updated Projection to 2038
por: Kwak, Kyeongmin, et al.
Publicado: (2021)

Clinical Case Conference: Strategies for Transferring From Methadone to Buprenorphine
por: Hill, Duncan, et al.
Publicado: (2022)

Subcutaneous Extended-Release Buprenorphine Use in Pregnancy
por: Towers, Craig V., et al.
Publicado: (2020)

Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
por: Tiberg, Fredrik, et al.
Publicado: (2015)

Neuropathy and neural plasticity in the subcutaneous white adipose depot
por: Blaszkiewicz, Magdalena, et al.
Publicado: (2019)

Transferring Patients From Methadone to Buprenorphine: The Feasibility and Evaluation of Practice Guidelines
por: Lintzeris, Nicholas, et al.
Publicado: (2018)

Subcutaneous Implants of Buprenorphine-Cholesterol-Triglyceride Powder in Mice
por: DeTolla, L., et al.
Publicado: (2014)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

2038. Invasive Mucormycosis Management: Mucorales PCR Provides Important, Novel Diagnostic Information
por: Wilgers, Kyle, et al.
Publicado: (2018)

Germany’s decision to phase out coal by 2038 lags behind citizens‘ timing preferences
por: Rinscheid, Adrian, et al.
Publicado: (2019)

Abdominal Subcutaneous Adipose Tissue: A Protective Fat Depot?
por: Porter, Stacy A., et al.
Publicado: (2009)

Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate
por: Taylor, Douglas J., et al.
Publicado: (2022)

Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots
por: Agrawal, Saaket, et al.
Publicado: (2022)

Opioid prescribing in Australia: too much and not enough
por: Dunlop, Adrian J, et al.
Publicado: (2021)

Subcutaneous Implants of a Cholesterol-Triglyceride-Buprenorphine Suspension in Rats
por: Guarnieri, M., et al.
Publicado: (2017)

2038. Antimicrobial Stewardship (AS) Recognition, Confidence, and Organizational Factors: Multi-center Survey of Bedside Nurses
por: Monsees, Elizabeth, et al.
Publicado: (2019)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Gluteal Subcutaneous Atrophy After Depot Steroid Injection for Allergic Rhinitis
por: Ameratunga, Rohan
Publicado: (2012)

Abdominal subcutaneous adipose tissue: a favorable adipose depot for diabetes?
por: Chen, Peizhu, et al.
Publicado: (2018)

Population Pharmacokinetics of a Monthly Buprenorphine Depot Injection for the Treatment of Opioid Use Disorder: A Combined Analysis of Phase II and Phase III Trials
por: Jones, Aksana K., et al.
Publicado: (2020)

Bioavailability of subcutaneous and intramuscular administrated buprenorphine in New Zealand White rabbits
por: Askar, Raad, et al.
Publicado: (2020)

Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine
por: Gilman, Mark, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_d2j0d75s0gtf8oq0q735qv6grs